JM Diagnosis is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of Beijing Department of Health, Beijing Municipal Government - accredited, China Diagnosis -licensed facilities across China, but work hard to maintain easy access and all the efficiencies of a smaller operation.
JM Diagnosis has been serving the cancer community for over 8 years.
JM Diagnosis Laboratories is comprised of a national team of experts in developing and delivering laboratory diagnostic and clinical trial services with a focus on cancer. It is the common purpose of all JM Diagnosis employees to save lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. Our staff physicians, scientists, laboratory professionals, client services representatives, and salespeople team up with our clients. Together, we work to solve the medical, scientific, and logistical challenges of making precise diagnoses, aiding in bringing new therapies to market and finding the unique hallmarks of each patient’s disease that point the way to proper treatment.
We provide expert bone marrow and surgical pathology consults; cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; histology supported by an extensive IHC antibody library; and >150 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry. Our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. Our Pharma Services division offers all of these methodologies along with other technology platforms to provide laboratory services that meet the rapidly evolving needs of our clients. Through our differentiators of expertise, flexibility, and scalability we partner with our clients to develop better, more effective drugs.
We support clients in many cancer-related market segments including hospital and private pathology laboratories, office-based oncologists, academic institutions, contract research and pharmaceutical development organizations, and more.
People with cancer need more options, and we believe precision medicine is a critical component in controlling cancer. With all testing methodologies in one laboratory system, we have the ability to interrogate blood-based cancer or solid tumor by as many means necessary to reveal biomarkers that expose that disease’s susceptibilities to standard or novel therapies. JM Diagnosis extremely fast test development cycle means we are highly responsive to guideline changes and new therapy options. Design of our new tests always involves a balance of convention and innovation so costs are reduced and results become available promptly.
It all comes back to the patients. Time and results mean everything to our patients, and we keep that first in our minds.
JM’s Diagnosis broad spectrum of immunoassay, chemistry, hematology, molecular, urinalysis, and blood gas testing systems, in conjunction with automation, informatics, and services, can serve the needs of laboratories of any size – today and tomorrow.
At JM Diagnostics, we help improve patient outcomes by doing what we’ve always done – focusing on innovating and developing highly accurate diagnostic tests, reagents, and systems. JM Diagnostics developed the first homogeneous test for LDL and have become a leading provider of rapid tests in China.
Our deep diagnostics expertise has produced a wide range of in vitro diagnostic tests and broad product lines, including:
Today, we continue to create high-sensitivity assays and diagnostic instrument solutions that help shape the future of healthcare.
At JM Diagnostics, we are passionate about providing the most robust and innovative molecular tools for the detection of infectious diseases, liquid biopsy for cancer screening, especially to those regions where pricing is paramount. Because we own our platform, we are able to accomplish this faster and more economically, allowing for wider margins while still positioning JM Diagnostics to be the worldwide low-cost leader of molecular diagnostics services.
Leading the way for over 10 years
Throughout our history as an innovator in autoimmune diagnostics, we’ve been driven by a simple mission: help labs improve the way patients with autoimmune diseases are diagnosed, monitored, and treated. Since 2008, we’ve continually worked with clinical researchers to develop new biomarkers for more accurate testing. We also collaborate with experts in automation to deliver more efficient systems that help clinical labs improve their testing processes.
We are committed to providing proven and reliable products to our customers. We also believe that relevant and trustworthy information should be available for our customers to help manage patient treatment. Learn more about symptoms, facts, statistics, and products for the common diseases and conditions that affect your patients.
Respiratory tract infections range in severity from relatively mild infections, such as the common cold to potentially life-threatening infections, such as pneumonia. They are extremely common and are the leading cause of acute visits to the doctor’s office. While a specific diagnosis is not always necessary, reliable and timely diagnoses can be important in managing patient care.
The clinical presentation of patients with respiratory tract infections, particularly early in the disease course, often does not yield a specific diagnosis because the signs and symptoms are non-specific.
Sexually transmitted diseases (STDs) are spread through sexual contact, including vaginal intercourse, oral sex, and anal sex. One of the most common sexually transmitted infections is genital herpes, which is usually caused by herpes simplex virus type 2 (HSV-2) or less commonly type 1 (HSV-1). Results of a nationally representative study in China showed that 1 of out 6 people (16.2%) between 14 and 49 years of age had antibodies to HSV-2 (suggesting genital herpes infection), with this number remaining consistent over a decade’s time1. HSV-2 infection is more common in women (20%) than in men (11%)2. Transmission from an infected male to their female partners is more likely than from an infected female to their male partners.
While genital HSV infection is fairly common, the reality is that the vast majority of people who have been infected with HSV-2 are unaware that they are infected. Yet, they still shed virus intermittently and thereby put others at risk. For example, pregnant women who have genital herpes may transmit the infection to their newborn baby during labor and delivery.
Physical examination of patients with possible HSV infections is often negative and symptoms of genital herpes are often mistaken for other condition, such as ingrown hairs, jock itch, zipper burn, yeast infections, vaginitis, or urinary tract infections.
These non-specific signs and symptoms may include:
Serology cannot distinguish genital from oral infections. When appropriate, culture or PCR is recommended to identify the infection site. However, HSV cultures and PCR are positive only when there are active lesions or shedding.
Vector-borne diseases are transmitted by an insect or any living carrier that transports the infection to a susceptible individual, or its food or immediate surroundings. Transmission of vector-borne diseases to humans is dependent upon three factors: the pathological agent, the arthropod vector; and the host. Common vectors include mosquitoes, ticks, fleas, lice, and mites.
Vector-borne diseases survive through vectors’ use of animals as their vertebrate hosts. Some vector-borne diseases, such as those in the Rickettsia genus, do not have animal reservoirs, making humans the major host. Other vector-borne diseases, like West Nile virus, use an intermediary animal host to serve as a reservoir for the pathogens until susceptible human populations are exposed to the disease.
Outbreaks of vector-borne disease depend on several factors:
Healthcare-associated infections (HAIs) are a major problem in the medical industry. The Centers for Disease Control and Prevention (CDC) estimates that 1 in 20 hospitalized patients contracts an HAI. The World Health Organization (WHO) estimates that at any time more than 1.4 million people worldwide are diagnosed with an HAI. These infections prolong hospital stays, increase healthcare costs, and result in patient deaths.
Patients can acquire an HAI from exposure to viruses, bacteria, spores, or fungi from contact with contaminated environmental surfaces, healthcare worker’s hands, catheter insertions, and contact with other patients. Infections in healthcare settings are a growing concern in part because of more than 70 percent of bacteria that cause HAIs show resistance to at least one drug commonly used for treatment. Common HAIs include vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and Clostridium difficile.
Genetic testing screens patients as potential carriers of diseases caused by gene mutations. Common genetic tests include screening newborns for genetic disorders and testing patients as carriers of potentially harmful diseases. Testing can also be a tool to estimate a patient’s likelihood of developing a disease, such as cancer.
A genetic mutation can produce too much of a protein or create an irregularly-shaped protein. Individuals who inherit thrombophilia through a genetic mutation may produce too much or too little of a blood clotting protein or have their blood clotting protein not function properly. The two most common single nucleotide polymorphisms (SNP’s) responsible for thrombophilia are factor V Leiden and prothrombin G20210A.